Clinical Trials
7 trialsNCT00023881 2018-11-14
Bortezomib in Treating Patients With Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01162031 2018-05-21
Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia
Stanford University
Phase 2 Withdrawn
NCT01891968 2018-04-23
Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00818649 2017-12-28
Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01323920 2017-05-30
Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00510939 2009-08-14
HEMOS AML 0106
University of Bologna
Phase 2 Unknown
NCT00511069 2008-11-24
Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia
University of Bologna
Phase 2 Completed